Last reviewed · How we verify
EV71 +SIV
This is a bivalent vaccine combining inactivated enterovirus 71 (EV71) and simian immunodeficiency virus (SIV) components to elicit immune responses against both pathogens.
This is a bivalent vaccine combining inactivated enterovirus 71 (EV71) and simian immunodeficiency virus (SIV) components to elicit immune responses against both pathogens. Used for Hand, foot, and mouth disease prevention (EV71 component).
At a glance
| Generic name | EV71 +SIV |
|---|---|
| Sponsor | Zhejiang Provincial Center for Disease Control and Prevention |
| Drug class | Inactivated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
EV71 is a vaccine component targeting enterovirus 71, a major cause of hand, foot, and mouth disease in children. SIV component inclusion suggests this is a research or combination vaccine formulation. The exact mechanism of the SIV component in this marketed product is unclear from available public data.
Approved indications
- Hand, foot, and mouth disease prevention (EV71 component)
Common side effects
- Local injection site reactions
- Fever
- Myalgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |